Skip to main content
Click to learn more


Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed annually. While early detection through screening can substantially increase the 5‑year survival rate, 30–35% of eligible women in many regions do not undergo routine mammography. This gap in participation leads to delayed diagnoses, with more cancers detected at later, less treatable stages, resulting in more aggressive treatments, higher mortality rates and a greater burden on patients and health systems alike.


Impact


30-60%
Reduction in clinical workload
~30%
Decrease in the amount of diagnostic follow-ups
20%
Improvement in early cancer detection rates
Click to learn more


Skin cancer incidence is on the rise worldwide, with melanoma being a major contributor to cancer-related deaths despite high cure rates when detected early. However, there remains a gap in screening participation, with 30-40% of high-risk individuals not receiving regular skin examinations, leading to delays in diagnosis and more advanced disease stages. These factors impose a substantial clinical and economic burden on healthcare organisations, as later-stage treatments require more intensive and costly interventions.


Impact


73–87%
Time saved per mole review
~50%
Reduction in dermatology referrals
5x
Increase in patient screening capability
Click to learn more


Lung cancer remains the leading cause of cancer-related deaths globally, often diagnosed at late stages due to low screening participation. Despite evidence that low-dose CT (LDCT) screening reduces mortality, fewer than 10% of eligible high-risk individuals undergo screening. This results in missed opportunities for early intervention, placing a significant clinical and economic burden on healthcare systems, as advanced-stage treatments are more invasive, costly, and resource-intensive.


Impact


~79%
Reduction in radiologist workload
3-5x
Increase in screening throughput
2x
Increase in patient follow-up adherence